USANA Health Sciences, Inc. (USNA) Guidance & Earnings Results

On 2026-08-04 USANA Health Sciences, Inc. lowered guidance: "FY2026: Core Nutritional net sales $750M (prev $720-$765M); Hiya net sales $125M (prev $140-$155M); Rise Wellness net sales $35M (prev $65-$80M); Consolidated net sales $910M (prev $925M-$1.0B); Net loss $(11)M (prev…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-07-04 · read by EquiReason

USNAUSANA Health Sciences, Inc.Follow USNA — free

Packaged Foods · Consumer Defensive

—

Price chart with a free account

Market cap: 257.9M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 3 Nov, in 10 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Lowered	FY2026: Core Nutritional net sales $750M (prev $720-$765M); Hiya net sales $125M (prev $140-$155M); Rise Wellness net sales $35M (prev $65-$80M); Consolidated net sales $910M (prev $925M-$1.0B); Net loss $(11)M (prev $20M-$27M); Diluted EPS $(0.61) (prev $1.11-$1.45); Adjusted diluted EPS $0.76 (prev $1.95-$2.29); Adjusted EBITDA $87M (prev $101M-$109M) · full year
5 May 26	Reaffirmed	FY2026: Core Nutritional net sales $720-765M; Hiya net sales $140-155M; Rise Wellness net sales $65-80M; Consolidated net sales $925M-$1.0B; Net earnings $20-27M; Diluted EPS $1.11-1.45; Adjusted diluted EPS $1.95-2.29; Adjusted EBITDA $101-109M · full year
18 Feb 26	Mixed	FY2026 net sales guidance of $925M-$1.0B (flat to 8% growth); adjusted diluted EPS $1.95-$2.29. · full year
12 Jan 26	Raised	FY2025 preliminary ~$925M vs prior guidance ~$920M; FY2026 guidance $925M-$1.0B · full year
22 Oct 25	Lowered	FY2025 net sales guidance midpoint cut from $960M to $920M; EPS from $1.85 to $0.78 · full year
9 Oct 25	Lowered	Full year sales at or near lower end of prior range; EPS below range · full year

USANA Health Sciences, Inc. — questions

What guidance did USANA Health Sciences, Inc. give?: On 2026-08-04: "FY2026: Core Nutritional net sales $750M (prev $720-$765M); Hiya net sales $125M (prev $140-$155M); Rise Wellness net sales $35M (prev $65-$80M); Consolidated net sales $910M (prev $925M-$1.0B); Net loss $(11)M (prev $20M-$27M); Diluted EPS $(0.61) (prev $1.11-$1.45); Adjusted diluted EPS $0.76 (pre"
When does USANA Health Sciences, Inc. report earnings?: USANA Health Sciences, Inc.'s next earnings report is expected on 2026-11-03.

Every figure on this page comes from USANA Health Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.